ANT2681 | CAS#N/A

MedKoo Cat#: 535275 | Name: ANT2681

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ANT2681 is a novel Metallo-β-lactamase Inhibitor with Potential for Clinical Use in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae.

Chemical Structure

ANT2681

CAS#N/A

Theoretical Analysis

MedKoo Cat#: 535275

Name: ANT2681

CAS#: N/A

Chemical Formula: C12H12F2N8O4S2

Exact Mass: 434.0391

Molecular Weight: 434.40

Elemental Analysis: C, 33.18; H, 2.78; F, 8.75; N, 25.80; O, 14.73; S, 14.76

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

ANT2681; ANT-2681; ANT 2681

IUPAC/Chemical Name

5-((4-(2-Carbamimidoylhydrazine-1-carboxamido)-3,5-difluorophenyl)sulfonamido)thiazole-4-carboxamide

InChi Key

MIBPFKBBDUWQLA-UHFFFAOYSA-N

InChi Code

InChI=1S/C12H12F2N8O4S2/c13-5-1-4(2-6(14)7(5)19-12(24)21-20-11(16)17)28(25,26)22-10-8(9(15)23)18-3-27-10/h1-3,22H,(H2,15,23)(H4,16,17,20)(H2,19,21,24)

SMILES Code

O=C(C1=C(NS(=O)(C2=CC(F)=C(NC(NNC(N)=N)=O)C(F)=C2)=O)SC=N1)N

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 434.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Das S, Johnson A, McEntee L, Farrington N, Kirby A, Unsworth J, Jimenez- Valverde A, Kolamunnage-Dona R, Bousquet J, Alibaud L, Sable C, Zalacain M, Everett M, Hope W. Pharmacodynamics of the Novel Metallo-ß-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of NDM-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2020 Aug 10:AAC.01076-20. doi: 10.1128/AAC.01076-20. Epub ahead of print. PMID: 32778549. 2: Davies DT, Leiris S, Sprynski N, Castandet J, Lozano C, Bousquet J, Zalacain M, Vasa S, Dasari PK, Pattipati R, Vempala N, Gujjewar S, Godi S, Jallala R, Sathyap RR, Darshanoju NA, Ravu VR, Juventhala RR, Pottabathini N, Sharma S, Pothukanuri S, Holden K, Warn P, Marcoccia F, Benvenuti M, Pozzi C, Mangani S, Docquier JD, Lemonnier M, Everett M. ANT2681: SAR Studies Leading to the Identification of a Metallo-β-lactamase Inhibitor with Potential for Clinical Use in Combination with Meropenem for the Treatment of Infections Caused by NDM- Producing Enterobacteriaceae. ACS Infect Dis. 2020 Aug 20. doi: 10.1021/acsinfecdis.0c00207. Epub ahead of print. PMID: 32786279.